Immune Checkpoint Inhibition for Unresectable Malignant Pleural Mesothelioma.

Drugs
Wanyuan Cui, Sanjay Popat

Abstract

Immune checkpoint inhibitors (ICI) have shown important but variable efficacy in mesothelioma despite a lack of strong biological rationale. Initial trials assessed ICI monotherapy in patients with relapsed mesothelioma, with objective response rates (ORR) between 4.5 and 29%, median progression-free survival (PFS) between 2.5-6.2 months, and median overall survival (OS) between 7.7 and 18.0 months. In randomised trials of chemotherapy pre-treated patients, nivolumab was recently shown to improve PFS compared to placebo, but tremelimumab was not superior to placebo, and there was no difference in OS between pembrolizumab and chemotherapy. However, response to combination ICI appear more promising in both pre-treated and treatment-naïve mesothelioma. The randomised Phase 3 trial of upfront ipilimumab-nivolumab versus platinum-pemetrexed chemotherapy demonstrated improved OS favouring ipilimumab-nivolumab (HR 0.74, 96.6% CI 0.60-0.91; p = 0.0020), establishing this regimen as a new standard of care, especially in non-epithelioid histological subtypes. However, initially PFS was poorer in the ipilimumab-nivolumab than chemotherapy treatment arms. A single-arm Phase 2 trial of upfront platinum chemotherapy and durvalumab met its pr...Continue Reading

References

Apr 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·F Stephen HodiGlenn Dranoff
Jun 27, 2003·Proceedings of the National Academy of Sciences of the United States of America·Giao Q PhanSteven A Rosenberg
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nicholas J VogelzangPaolo Paoletti
Jun 14, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Laurie Kazan-Allen
Aug 2, 2005·Lancet·Bruce W S RobinsonRichard A Lake
Jun 27, 2006·Journal of Immunotherapy·Ajay V MakerSteven A Rosenberg
Nov 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey S WeberEvan Hersh
Feb 20, 2010·American Journal of Respiratory and Critical Care Medicine·Joost P HegmansJoachim G Aerts
Jun 23, 2010·Cancer Immunology, Immunotherapy : CII·Noriyuki YamadaMasaharu Nishimura
Nov 4, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carlos AlfaroIgnacio Melero
Dec 3, 2011·The European Respiratory Journal·Ronald A M DamhuisJacobus A Burgers
Mar 29, 2013·Nature Reviews. Cancer·Michael HölzelThomas Tüting
Jun 14, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aaron Scott MansfieldEugene D Kwon
Jan 9, 2015·Indian Journal of Occupational and Environmental Medicine·Claudio Bianchi, Tommaso Bianchi
Feb 11, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dirk SchadendorfJedd D Wolchok
Dec 15, 2015·American Journal of Respiratory and Critical Care Medicine·Robin CornelissenJoachim G J V Aerts
Mar 17, 2016·Human Pathology·Christelle Combaz-LairSylvie Lantuejoul
Jul 26, 2017·Nature Reviews. Cancer·Timothy A YapDean A Fennell
Dec 21, 2017·The New England Journal of Medicine·Mark YarchoanElizabeth M Jaffee
Feb 9, 2018·Respiration; International Review of Thoracic Diseases·Greta CarioliEva Negri
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Jan 1, 2017·JCO Precision Oncology·Russell BonnevilleSameek Roychowdhury
Jun 5, 2018·The New England Journal of Medicine·Mark A SocinskiUNKNOWN IMpower150 Study Group
Jun 17, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Josine Quispel-JanssenPaul Baas
Jul 30, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Surein ArulanandaThomas John
Aug 3, 2018·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A Bernard-TessierC Massard
Oct 4, 2018·The New England Journal of Medicine·Luis Paz-AresUNKNOWN KEYNOTE-407 Investigators
Oct 14, 2018·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aaron S MansfieldGeorge Vasmatzis
Nov 16, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Michael RosskampHarlinde De Schutter
Nov 20, 2018·Translational Lung Cancer Research·Lisa BrusselmansKevin Lamote
Jun 6, 2019·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Morihito OkadaYuichiro Ohe
Sep 29, 2019·The New England Journal of Medicine·Matthew D HellmannSuresh S Ramalingam

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.